Edesa Biotech, Inc. EDSA
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-2.63
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$7.2M | — | — | $12.5M |
| 2024 | — | -$6.2M | — | — | $2.0M |
| 2023 | — | -$8.4M | — | -$6.6M | $7.0M |
| 2022 | — | -$17.5M | — | -$12.3M | $9.4M |
| 2021 | $0 | -$13.3M | — | -$13.7M | $13.1M |
| 2020 | $328,801 | -$6.4M | — | -$5.0M | $6.6M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Nijhawan Pardeep | Chief Executive Officer | 2026-06-16 | Grant | 153,550 | $5.21 |
| Nijhawan Pardeep | Chief Executive Officer | 2026-06-01 | Grant | 1,671 | — |
| Marshall Patrick | director | 2026-05-27 | Grant | 19,000 | — |
| MacDonald Sean Arthur | director | 2026-05-27 | Grant | 19,000 | — |
| Chypyha Joan | director | 2026-05-27 | Grant | 19,000 | — |
| Weiler Peter J. | Chief Financial Officer | 2026-05-27 | Grant | 64,609 | — |
| Brooks Michael J | President | 2026-05-27 | Grant | 64,609 | — |
| Sistilli Carlo | director | 2026-05-27 | Grant | 19,000 | — |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -2.63 (distress)
- Working capital / assets 0.771
- Retained earnings / assets -4.871
- EBIT / assets -0.585
- Equity / liabilities 11.545
Source: SEC EDGAR filings · CIK 0001540159 · as of 2025-09-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.